Evidence mapPaperPMID 36633732Full record

SynthesisAdvances in therapy2023

Obesity Burden and Impact of Weight Loss in Saudi Arabia: A Modelling Study.

Saleh A Alqahtani, Hussain A Al-Omar, Ali Alshehri, Abdulmohsen Abanumay, Hana Alabdulkarim, Ali Alrumaih, Mahmoud S Eldin, Volker Schnecke

Open access · hybridAbstract readSystematic Review
In one paragraph

Synthesis in Advances in therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
4.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. A systematic review of obesity burden in Saudi Arabia: Prevalence and associated co-morbidities.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2024
    Review
  8. Article
  9. Article
  10. The Economic Impact of Obesity in Turkey: A Micro-Costing Analysis.ClinicoEconomics and outcomes research : CEOR · 2024
    Article
  11. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 3 countries.

Saleh A Alqahtani *Division of Gastroenterology and Hepatology, Johns Hopkins University, Baltimore, MD, USA.
Hussain A Al-Omar *Department of Clinical Pharmacy, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh, 11451, Saudi Arabia. halomar@ksu.edu.sa.ORCID http://orcid.org/0000-0002-0765-0466
Ali AlshehriObesity Medicine Department, Obesity, Endocrine & Metabolism Centre, King Fahad Medical City, Riyadh, Saudi Arabia.
Abdulmohsen AbanumayNovo Nordisk, Riyadh, Saudi Arabia.
Hana AlabdulkarimDrug Policy and Economic Centre, Ministry of National Guards Health Affairs, Riyadh, Saudi Arabia.
Ali AlrumaihPharmaceutical Care Department, Medical Services Directorate, Ministry of Defence, Riyadh, Saudi Arabia.
Mahmoud S EldinNovo Nordisk, Riyadh, Saudi Arabia.
Volker SchneckeNovo Nordisk A/S, Søborg, Denmark.
Saudi Heart Association · SAJohns Hopkins University · USKing Fahd Medical City · SAKing Saud University · SANational Guard Health Affairs · SANovo Nordisk (Denmark) · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundObesity and its complications are associated with morbidity, mortality and high economic cost in Saudi Arabia. Estimating this impact at the population level and potential benefits to be gained from obesity reduction is vital to underpin policy initiatives to prevent disease risks.

methodsWe combined data in an adapted version of the value of weight loss simulation model, to predict reductions in complication rates and cost savings achievable with 15% weight loss in Saudi Arabia over 10 years. To obtain model inputs, we conducted a systematic literature review (SLR) to identify data on the prevalence of obesity and its complications in Saudi Arabia, and surveyed specialist physicians and hospital administrators in public (governmental) and private healthcare sectors. We used combinations of age, sex, obesity and type 2 diabetes (T2D) rates in Saudi Arabia to sample a United Kingdom (UK) cohort, creating a synthetic Saudi Arabia cohort expected to be representative of the population.

resultsThe synthetic Saudi Arabia cohort reflected expected comorbidity prevalences in the population, with a higher estimated prevalence of T2D, hypertension and dyslipidaemia than the UK cohort in all age groups. For 100,000 people with body mass index 30-50 kg/m

conclusionsSustained weight loss could significantly alleviate the burden of obesity-related complications in Saudi Arabia. Adopting obesity reduction as a major policy aim, and ensuring access to support and treatment should form an important part of the transformation of the healthcare system, as set out under 'Vision 2030'.

Indexed as

Diabetes Mellitus, Type 2HypertensionHumansObesityPrevalenceSaudi ArabiaWeight LossCost savingsEconomic burdenHealthcare costsObesityObesity-related complicationOverweightPrevalenceSaudi ArabiaVision 2030Weight loss

Identifiers

PMID36633732
PMCPMC9988771
OpenAlexW4315752515

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.